Form 4: Tandem Diabetes Director Twomey Reports RSU Vesting, New Grant
Insider Transaction Report
Christopher J. Twomey, a director at Tandem Diabetes Care Inc., reported the vesting of 8,759 restricted stock units and the grant of 10,220 new units.
Summary
- Director Christopher J. Twomey reported transactions involving Tandem Diabetes Care Inc. common stock and restricted stock units (RSUs).
- On May 21, 2026, 8,759 restricted stock units (RSUs) granted on May 21, 2025, vested and converted into 8,759 shares of common stock.
- On May 20, 2026, Twomey was granted 10,220 new restricted stock units (RSUs).
- These new RSUs are scheduled to vest on the one-year anniversary of the grant date, May 20, 2027.
- Following these transactions, Twomey directly holds 24,434 shares of common stock and 10,220 RSUs.
- Additionally, 5,112 shares are held indirectly by the Chris J. Twomey and Rebecca J. Twomey Family Trust, and 7,568 shares are held indirectly by Twomey Family Investments, LLC.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive event, reflecting routine director compensation and an increase in the director's direct share ownership, which aligns insider interests with shareholders.
Positives
- Director Christopher J. Twomey received a new grant of 10,220 restricted stock units, indicating continued equity-based compensation.
- 8,759 restricted stock units vested and converted into common stock, increasing the director's direct ownership in the company.
Negatives
- No specific negative financial or operational information is contained in this Form 4 filing.
Risks
- No specific risks related to the company's operations or financial health are mentioned in this Form 4 filing.
Future Outlook
The filing indicates that 10,220 new Restricted Stock Units granted on May 20, 2026, are expected to vest on the one-year anniversary of the grant date, May 20, 2027, subject to the terms of the 2023 Long-Term Incentive Plan.
Industry Context
StockSavvy.ai notes that equity compensation, particularly through restricted stock units, is a standard practice across industries to align the interests of directors and executives with those of shareholders. This filing reflects a routine compensation event for a director at Tandem Diabetes Care Inc., consistent with typical corporate governance practices for publicly traded companies.
Comparison to Industry Standards
- Equity compensation through RSUs is a common practice for directors in the biotechnology and medical device sectors, similar to companies like Dexcom (DXCM) or Insulet (PODD), which also utilize performance-based or time-based equity awards to incentivize leadership.
- The grant and vesting schedule align with typical long-term incentive plans designed to retain talent and promote long-term value creation.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Substitute Power of Attorney | Shannon M. Hansen, an attorney-in-fact for several individuals including Christopher J. Twomey, appointed Jerilyn Laskie as a substitute attorney-in-fact to execute and file Section 16(a) documents with the SEC. | 2026-05-20 | This is a procedural update to facilitate SEC filings for insiders, ensuring continuity and efficiency in compliance with reporting requirements. It does not alter the underlying powers or responsibilities of the individuals involved but streamlines the administrative process. |
Related Party Transactions
- Indirect beneficial ownership of 5,112 shares is held by the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD September 20, 2002.
- Indirect beneficial ownership of 7,568 shares is held by Twomey Family Investments, LLC, where the Reporting Person is co-manager and shares voting and investment power.
Stakeholder Impact
- Shareholders: The vesting and grant of RSUs align the director's interests with shareholders by increasing equity ownership and providing future incentives.
Next Steps
- The 10,220 Restricted Stock Units granted on May 20, 2026, are expected to vest on May 20, 2027.
Key Dates
| Date | Description |
|---|---|
| 2002-09-20 | Date of establishment for the Chris J. Twomey and Rebecca J. Twomey Family Trust UTD. |
| 2022-04-19 | Date of Power of Attorney for Dick P. Allen and Elizabeth A. Gasser. |
| 2022-04-20 | Date of Power of Attorney for Peyton R. Howell, Rebecca B. Robertson, John F. Sheridan, Christopher J. Twomey, and Leigh A. Vosseller. |
| 2022-04-21 | Date of Power of Attorney for Ricky A. Carpenter, Kathleen McGroddy-Goetz, Susan M. Morrison, and Rajwant S. Sodhi. |
| 2022-06-15 | Date of Power of Attorney for Myoungil Cha and Joao Malagueira. |
| 2024-06-21 | Date of Power of Attorney for Jean-Claude Kyrillos. |
| 2025-05-21 | Grant date of 8,759 Restricted Stock Units to Christopher J. Twomey. |
| 2025-11-11 | Date of Power of Attorney for Sandra W. Beaver. |
| 2026-05-20 | Grant date of 10,220 Restricted Stock Units to Christopher J. Twomey; Date of execution of Substitute Power of Attorney. |
| 2026-05-21 | Vesting and conversion date of 8,759 Restricted Stock Units into common stock. |
| 2026-05-22 | Signature date of the Form 4 filing by Jerilyn Laskie, Attorney-in-Fact. |
| 2027-05-20 | Expected vesting date for the 10,220 Restricted Stock Units granted on May 20, 2026. |
Recommendation
holdThis Form 4 filing details routine insider transactions related to equity compensation (RSU vesting and a new grant). Such events are generally expected and do not typically provide new information that would warrant a change in investment recommendation. The transactions reflect standard compensation practices and an increase in the director's direct equity stake, which is a neutral to slightly positive signal for alignment of interests. Therefore, a "hold" recommendation is appropriate as this filing does not present a compelling reason to buy or sell based solely on its content.
Keywords
Tandem Diabetes Care, TNDM, Christopher J. Twomey, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, Director, Stock Grant
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.